Injected Anandamide Was Not a Reliable Stand-In for CB1 Activation in One Mouse Experiment
A molecule known to activate CB1 does not necessarily produce every whole-animal effect through CB1. In one mouse experiment, anandamide’s suppression of responding was not blocked by rimonabant.
The antagonist comparison distinguished the drugs
Singh and colleagues tested THC, CP55,940 and anandamide on food-maintained responding. Rimonabant antagonized the rate-decreasing effects of THC and CP55,940, but not anandamide. Repeated THC also failed to produce the same cross-tolerance pattern for anandamide.
The compound’s name did not establish the mechanism
The authors discuss rapid anandamide metabolism and possible contributions from metabolites as explanations for differences between species and administration routes. These were mechanistic possibilities, not direct identification of the responsible metabolite in this experiment. The discussion notes that inhibiting anandamide breakdown can make its CB1-mediated effects clearer in other research.
Keep the conclusion within the tested conditions
The findings do not mean anandamide never acts at CB1. They limit its use as a selective CB1 probe when administered systemically under these conditions. They also do not establish that injecting an endogenous cannabinoid recreates its normal synaptic signaling. For interpreting cannabis research, the relevant distinction is between a ligand’s known receptor activity and the mechanism actually supported for the observed whole-animal response.
Related analysis: Outcome-specific cannabinoid cross-tolerance.
Research cited
Singh H, Schulze DR, McMahon LR. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia (2011).
